9:29 AM
Mar 08, 2019
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Boehringer reports first data for IL-36R inhibitor in rare type of psoriasis

Boehringer said BI 655130 cleared symptoms of generalized pustular psoriasis within one week in a Phase I trial in seven patients experiencing an acute moderate-to-severe flare of the disease. BI 655130 is a mAb against IL-36R.

Boehringer Ingelheim GmbH (Ingelheim, Germany) said there are no FDA-approved therapies for generalized pustular psoriasis.


Read the full 236 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >